[go: up one dir, main page]

MXPA03001391A - Uso de anticuerpos contra complejos especificos mhc-peptidos. - Google Patents

Uso de anticuerpos contra complejos especificos mhc-peptidos.

Info

Publication number
MXPA03001391A
MXPA03001391A MXPA03001391A MXPA03001391A MXPA03001391A MX PA03001391 A MXPA03001391 A MX PA03001391A MX PA03001391 A MXPA03001391 A MX PA03001391A MX PA03001391 A MXPA03001391 A MX PA03001391A MX PA03001391 A MXPA03001391 A MX PA03001391A
Authority
MX
Mexico
Prior art keywords
antibodies against
specific mhc
peptide complexes
against specific
mhc
Prior art date
Application number
MXPA03001391A
Other languages
English (en)
Inventor
Petrus Gerardus A Steenbakkers
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of MXPA03001391A publication Critical patent/MXPA03001391A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Rehabilitation Therapy (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invencion describe un metodo para diagnosticar la actividad de enfermedad autoinmune mediante la deteccion de la presencia de un complejo autoinmune especifico de MHC-peptido en un paciente que sufre de una enfermedad autoinmune. El complejo de MHC-peptido se asocia con artritis reumatoide. Los anticuerpos monoclonales a utilizarse para este metodo tambien se describen. Los anticuerpos tambien pueden utilizarse para propositos terapeuticos.
MXPA03001391A 2000-08-14 2001-08-08 Uso de anticuerpos contra complejos especificos mhc-peptidos. MXPA03001391A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00202844 2000-08-14
PCT/EP2001/009136 WO2002014870A2 (en) 2000-08-14 2001-08-08 Use of antibodies against specific mhc-peptide complexes

Publications (1)

Publication Number Publication Date
MXPA03001391A true MXPA03001391A (es) 2004-05-04

Family

ID=8171913

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03001391A MXPA03001391A (es) 2000-08-14 2001-08-08 Uso de anticuerpos contra complejos especificos mhc-peptidos.

Country Status (14)

Country Link
US (1) US7320873B2 (es)
EP (1) EP1319184B1 (es)
JP (1) JP2004506901A (es)
CN (1) CN1305906C (es)
AR (1) AR033832A1 (es)
AT (1) ATE368225T1 (es)
AU (2) AU9373501A (es)
BR (1) BR0113213A (es)
CA (1) CA2415353A1 (es)
DE (1) DE60129572T2 (es)
ES (1) ES2290171T3 (es)
IL (2) IL154000A0 (es)
MX (1) MXPA03001391A (es)
WO (1) WO2002014870A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214373B2 (en) 2001-07-24 2007-05-08 Yale University Methods, compositions and kits relating to chitinases and chitinase-like molecules and inflammatory disease
AU2005247950B2 (en) * 2004-05-27 2012-02-02 Receptor Logic, Inc. Antibodies as T cell receptor mimics, methods of production and uses thereof
EP1933864A4 (en) * 2005-09-07 2009-12-16 Receptor Logic Ltd ANTIBODIES AS T-CELL RECEPTOR MIMICS, METHOD OF MANUFACTURE AND ITS USES
EP2124987A4 (en) * 2007-01-19 2012-05-02 Kai Pharmaceuticals Inc METHOD OF USE OF EPSILON HEMMER COMPOUNDS FOR PAIN LIFTING
WO2009151487A1 (en) * 2008-06-13 2009-12-17 Receptor Logic, Inc. Methods of assaying vaccine potency
WO2010141658A1 (en) * 2009-06-04 2010-12-09 The Regent Of The University Of Colorado Therapeutic compositions and methods for the prevention of autoimmune diseases
AU2011223660B2 (en) * 2010-03-02 2016-10-13 Novelmed Therapeutics, Inc. A method for inhibiting alternative pathway mediated disorders with anti-properdin antibodies that inhibit C5 interactions with properdin
EP2593480A2 (en) * 2010-07-15 2013-05-22 Technion Research & Development Foundation Ltd. Antibodies with t-cell receptor like specificity towards native complexes of mhc class ii and diabetes-associated autoantigenic peptides
EP2593551B1 (en) 2010-07-15 2016-09-14 Technion Research & Development Foundation Ltd. Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and glutamic acid decarboxylase (gad) autoantigenic peptides
US20130302329A1 (en) * 2010-09-21 2013-11-14 Trustees Of Boston University Diagnostic tests for immune reactivity with human endothelial cell growth factor
CN103476258B (zh) 2011-02-25 2017-04-26 默沙东公司 用作抗糖尿病药剂的新的环状氮杂苯并咪唑衍生物
WO2012162697A1 (en) 2011-05-26 2012-11-29 The Regents Of The University Of Colorado, A Body Corporate Compounds that modulate autoimmunity and methods of using the same
US9926366B2 (en) 2012-10-04 2018-03-27 Novelmed Therapeutics, Inc. Methods of treating a hemolytic disorder comprising administering anti-properdin antibodies
EP3152235B1 (en) 2014-05-29 2021-08-25 MacroGenics, Inc. Tri-specific binding molecules and methods of use thereof
EP3247384B1 (en) 2015-01-14 2023-10-04 The Regents of the University of Colorado, a body corporate In vitro method of diagnosis of type 1 diabetes with insulin mimotopes
CA3018727C (en) 2016-03-24 2024-03-26 The Regents Of The University Of Colorado, A Body Corporate Methods of treating autoimmune disease
CN110325209A (zh) 2017-02-24 2019-10-11 宏观基因有限公司 能够结合cd137和肿瘤抗原的双特异性结合分子及其用途
US11052060B2 (en) 2018-02-12 2021-07-06 The Regents Of The University Of Colorado, A Body Corporate Compounds and methods for treating autoimmunity
US11013707B2 (en) 2018-03-23 2021-05-25 The Regents Of The University Of Colorado, A Body Corporate Administration of oral methyldopa
CN111423504B (zh) * 2020-04-17 2021-03-26 安徽高安生物医学科技有限公司 黑色素瘤特异性抗原肽、肽复合物以及人工抗原呈递细胞
CN115960239B (zh) * 2023-01-03 2025-10-17 陕西脉元生物科技有限公司 特异性识别hcgp-39的单克隆抗体及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2103770T3 (es) 1990-11-26 1997-10-01 Akzo Nobel Nv Procedimiento de produccion de anticuerpos monoclonales.
WO1995002188A1 (en) 1993-07-12 1995-01-19 The Regents Of The University Of California Assay for ykl-40 as a marker for degradation of mammalian connective tissue matrices
CA2164498C (en) * 1993-07-09 2007-09-11 Paul A. Price Assay for ykl-40 as a marker for degradation of mammalian connective tissue matrices
WO1998012221A1 (de) * 1996-09-18 1998-03-26 Gerhild Wildner Peptide als diagnostikum und therapeutikum für autoimmunerkrankungen
IL122233A (en) 1996-12-06 2001-04-30 Akzo Nobel Nv Method of generating monoclonal antibodies to cell wall and pharmaceutical preparations and diagnostic agents containing them

Also Published As

Publication number Publication date
ATE368225T1 (de) 2007-08-15
CN1447919A (zh) 2003-10-08
EP1319184A2 (en) 2003-06-18
IL154000A (en) 2010-02-17
AR033832A1 (es) 2004-01-07
CN1305906C (zh) 2007-03-21
CA2415353A1 (en) 2002-02-21
DE60129572T2 (de) 2008-04-17
US7320873B2 (en) 2008-01-22
EP1319184B1 (en) 2007-07-25
AU9373501A (en) 2002-02-25
ES2290171T3 (es) 2008-02-16
JP2004506901A (ja) 2004-03-04
AU2001293735B2 (en) 2006-05-25
WO2002014870A2 (en) 2002-02-21
BR0113213A (pt) 2003-07-08
WO2002014870A3 (en) 2002-08-15
IL154000A0 (en) 2003-07-31
DE60129572D1 (de) 2007-09-06
US20040137514A1 (en) 2004-07-15

Similar Documents

Publication Publication Date Title
MXPA03001391A (es) Uso de anticuerpos contra complejos especificos mhc-peptidos.
PH12012501089A1 (en) Therapeutic human anti-il-1r1 monoclonal antibody
AU2555297A (en) Monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
EP1285271A4 (en) DIAGNOSIS, PROPHYLAXIS AND TREATMENT OF MORBUS CROHN THROUGH THE USE OF OMPC ANTIGENS (04.12.03)
EP1470146A4 (en) ANTIBODIES AGAINST ANTIGEN MUC18
EP1613347A4 (en) BETA AMYLOID PEPTIDE DETECTING HUMANIZED ANTIBODIES
EP1485130A4 (en) REAGENTS AND THERAPEUTIC METHODS OF AUTOIMMUNE DISEASES
AU3002699A (en) Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypesthereof, using microbial uc panca antigens
BG101024A (bg) Моноклонално антитяло срещу сd44v6
NZ331299A (en) Antibody variants with reduced affinity for a cell-surface antigen
ITMI20031127A1 (it) Anticorpi anti-hgf-r e loro uso
EP1742654A4 (en) ANTI-LFL2 ANTIBODIES FOR THE DIAGNOSIS, FORECAST AND TREATMENT OF CANCER
TR200103432T2 (tr) Engelleyici monoklonal VLA-1 antikoru ve enflamasyonlu hastalıkların tedavisinde kullanımı.
IT1307864B1 (it) Metodo diagnostico per il riconoscimento di neoplasie umane attraversola determinazione dell'isoforma ctn-c della tn-c, frammenti di
AU2002341090A1 (en) Use of a protein of the crmp family for treating diseases related to the immune system
AU4865997A (en) Monoclonal antibodies against a human act and serine protease complex
AU4098201A (en) Method for diagnosing efficacy of xenotypic antibody therapy
MXPA03009138A (es) Produccion de anticuerpos monoespecificos policlonales, contra variantes del receptor activador del plasminogeno de tipo uroquinasa (upar) del4, del5 y del4+5 y su uso para propositos de diagnostico y terapeutico.
EA199800959A1 (ru) ПРИМЕНЕНИЕ ГЕНЕТИЧЕСКОЙ МОДИФИКАЦИИ В ГЕНЕ b3- СУБЪЕДИНИЦЫ ЧЕЛОВЕЧЕСКОГО G-ПРОТЕИНА ДЛЯ ДИАГНОСТИКИ ЗАБОЛЕВАНИЙ
GB0014878D0 (en) Neurotransmission disorders
MD1656G2 (ro) Metodă de diagnosticare a proceselor autoimune în hepatitele cronice
UA10262A (uk) Спосіб ультразвукової діагностики стану судин головного мозку
FR2832155B1 (fr) Anticorps stimulant la production d'il-1ra
UA34205A (uk) Спосіб визначення захисної функції плаценти

Legal Events

Date Code Title Description
GB Transfer or rights
FG Grant or registration